文献速递白血病

儿童急性淋巴细胞白血病全转录组分析:DFCI ALL联盟16-001方案报告

Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001.
PubMed 文献 · Blood Adv · 2022-01-01

在DFCI ALL联盟16-001前瞻性多中心3期临床试验中,173例新诊断儿童ALL患者接受RNA测序可行性分析。RNA测序在157例(91%)中检出至少1种变异,融合检测与传统细胞遗传学100%一致,额外发现56种基因融合,并支持B-ALL分子亚分类。

要点

  • RNA测序在91%(157/173)的儿童ALL中检出至少1种遗传学变异。
  • 融合检测与传统细胞遗传学分析100%一致,并额外发现56种基因融合。
  • RNA测序支持B-ALL分子亚分类,并检出RAS-MAPK通路等非 synonymous 突变。

核心结论

  • RNA测序可检出传统方法未发现的多种临床相关遗传学变异,支持将该技术整合入儿童ALL一线临床试验。

研究设计与样本

  • DFCI ALL联盟16-001前瞻性多中心3期临床试验,纳入173例同意可选研究且有样本可用于RNA测序的新诊断儿童ALL患者。

主要发现

  • RNA测序在157例(91%)患者中检出至少1种变异。
  • 融合检测与传统细胞遗传学分析结果100%一致。
  • RNA测序额外发现56种基因融合,其中许多具有预后或治疗意义。
  • 基因表达谱将B-ALL进一步分为多个分子亚组:高超二倍体(n=36)、ETV6-RUNX1/-like(n=31)、TCF3-PBX1(n=7)、KMT2A重排(KMT2A-R;n=5)、21号染色体内部扩增(iAMP21)(n=1)、亚二倍体(n=1)、费城染色体(Ph)阳性/Ph样(n=16)、DUX4-R(n=11)、PAX5改变(PAX5 alt;n=11)、PAX5 P80R(n=1)、ZNF384-R(n=4)、NUTM1-R(n=1)、MEF2D-R(n=1)及其他(n=10)。
  • RNA测序在93例(54%)患者中检出141个非同义突变,最常见为RAS-MAPK通路突变。

关键数值与推荐

  • RNA测序检出至少1种变异的患者比例为91%(157/173)。
  • 融合检测与传统细胞遗传学分析的一致性为100%。
  • RNA测序额外发现的基因融合数为56种。
  • Ph样基因特征预测在79例中74例(94%)一致。

临床怎么用

  • 作者认为,RNA测序检出了传统方法未发现的多种临床相关遗传学变异,支持将该技术整合入儿童ALL一线临床试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The molecular hallmark of childhood acute lymphoblastic leukemia (ALL) is characterized by recurrent, prognostic genetic alterations, many of which are cryptic by conventional cytogenetics. RNA sequencing (RNA-seq) is a powerful next-generation sequencing technology that can simultaneously identify cryptic gene rearrangements, sequence mutations and gene expression profiles in a single assay. We examined the feasibility and utility of incorporating RNA-seq into a prospective multicenter phase 3 clinical trial for children with newly diagnosed ALL. The Dana-Farber Cancer Institute ALL Consortium Protocol 16-001 enrolled 173 patients with ALL who consented to optional studies and had samples available for RNA-seq. RNA-seq identified at least 1 alteration in 157 patients (91%). Fusion detection was 100% concordant with results obtained from conventional cytogenetic analyses. An additional 56 gene fusions were identified by RNA-seq, many of which confer prognostic or therapeutic significance. Gene expression profiling enabled further molecular classification into the following B-cell ALL (B-ALL) subgroups: high hyperdiploid (n = 36), ETV6-RUNX1/-like (n = 31), TCF3-PBX1 (n = 7), KMT2A-rearranged (KMT2A-R; n = 5), intrachromosomal amplification of chromosome 21 (iAMP21) (n = 1), hypodiploid (n = 1), Philadelphia chromosome (Ph)-positive/Ph-like (n = 16), DUX4-R (n = 11), PAX5 alterations (PAX5 alt; n = 11), PAX5 P80R (n = 1), ZNF384-R (n = 4), NUTM1-R (n = 1), MEF2D-R (n = 1), and others (n = 10). RNA-seq identified 141 nonsynonymous mutations in 93 patients (54%); the most frequent were RAS-MAPK pathway mutations. Among 79 patients with both low-density array and RNA-seq data for the Philadelphia chromosome-like gene signature prediction, results were concordant in 74 patients (94%). In conclusion, RNA-seq identified several clinically relevant genetic alterations not detected by conventional methods, which supports the integration of this technology into front-line pediatric ALL trials. This trial was registered at www.clinicaltrials.gov as #NCT03020030.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tran TH, Langlois S, Meloche C, et al. Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001. Blood Adv. 2022. PMID: 34933343. doi:10.1182/bloodadvances.2021005634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。